Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations
about
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptancePhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationTetrahydrobiopterin Supplementation: Elevation of Tissue Biopterin Levels Accompanied by a Relative Increase in Dihydrobiopterin in the Blood and the Role of Probenecid-Sensitive Uptake in Scavenging Dihydrobiopterin in the Liver and Kidney of RatsApplication of physiologically-based pharmacokinetic modeling to explore the role of kidney transporters in renal reabsorption of perfluorooctanoic acid in the rat.Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical StudiesPhysiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.Physiologically based pharmacokinetic modeling of human exposure to perfluorooctanoic acid suggests historical non drinking-water exposures are important for predicting current serum concentrations.Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Physiologically Based Pharmacokinetic Modeling of Palbociclib.The half-life and exposure of cefuroxime varied in newborn infants after a Caesarean section.Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.
P2860
Q26745824-15091811-357F-458C-82EE-1DE1CB33F3C3Q28088352-42C0805E-95A8-4DAC-BB89-311B87FC970DQ28554561-FAFFD27B-34C8-4F5F-9ADD-EBBAE5ACAD79Q36326773-78A6ABC3-BB8A-4479-987D-E1742E2AE4BEQ37420102-A34A93CD-19FA-440A-AE0D-B5742ECDF6FEQ37585421-6491C685-6A69-4CC7-A2E3-DE8D18803BCAQ37600383-25D2CCAC-00AD-4E46-B34D-39BA5195EB3FQ37726177-2B0B0874-BA39-4377-986D-7ED62510A037Q38233298-B545F4E7-45FF-45CA-BAD0-BF1409210BCAQ38664509-24B17A3B-CB00-4DDC-8FC5-B8ED44AD4CB6Q38690520-E561596A-76EC-4323-A092-9521E86B7025Q38699135-BF96630A-0B17-4184-952C-A9C4C54BDB36Q38804903-5BDB9373-0C82-4788-9763-4CC1A286DA91Q38844656-80DFFFA4-A6A6-431A-8374-DC44410CEADBQ38844658-C68CAC1A-0B18-4541-B508-EEAAE11DB350Q38887625-CDE0BD07-58E7-467A-B4CE-8795717A4AA9Q39178447-5B2087D8-32FA-4DA2-900D-C623680D99D5Q39612151-4871F010-81C5-4A91-A73A-A39475201061Q39725577-72369231-8CF3-4B4F-B26D-064F47A01E17Q40882268-2E2EA6A0-D707-41D4-9B7C-F459F94EAA39Q41850697-5644D656-FBBA-4A5C-805C-DFAC03C0590EQ44737065-A7802CCB-1889-4762-926B-6E69EDB4F257Q46119650-5B4EBA87-3938-4D58-A70F-924A0E2FC30EQ47592224-2C9A400A-8E56-4E1D-AC06-D0B008EA1535Q48114772-64CEE7DA-00DF-40F1-AFBD-C1C8E0CD1943
P2860
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Towards quantitation of the ef ...... etic modelling and simulations
@ast
Towards quantitation of the ef ...... etic modelling and simulations
@en
Towards quantitation of the ef ...... etic modelling and simulations
@nl
type
label
Towards quantitation of the ef ...... etic modelling and simulations
@ast
Towards quantitation of the ef ...... etic modelling and simulations
@en
Towards quantitation of the ef ...... etic modelling and simulations
@nl
prefLabel
Towards quantitation of the ef ...... etic modelling and simulations
@ast
Towards quantitation of the ef ...... etic modelling and simulations
@en
Towards quantitation of the ef ...... etic modelling and simulations
@nl
P2093
P2860
P921
P3181
P1476
Towards quantitation of the ef ...... etic modelling and simulations
@en
P2093
Anna Nordmark
Eva Gil Berglund
Jenny Huimin Zheng
Kathleen M. Giacomini
Manuela de L. T. Vieira
Shiew-Mei Huang
P2860
P2888
P304
P3181
P356
10.1007/S40262-013-0117-Y
P407
P577
2014-03-01T00:00:00Z
P5875
P6179
1033290276